Log In
BCIQ
Print this Print this
 

RGX-014/019

  Manage Alerts
Collapse Summary General Information
Company Rgenix Inc.
DescriptionCombination of two mAbs
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat triple negative breast cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today